



11/27/00

ATTORNEY DOCKET NO.: P- 4566

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
UTILITY PATENT APPLICATION TRANSMITTALPATENT
Total Pages _____FIRST NAMED INVENTOR OR APPLICATION IDENTIFIER: MICHEL VERHOEVEN
TITLE: STENTS AND METHODS FOR PREPARING STENTS FROM WIRES HAVING HYDROGEL COATING LAYERS THEREONAssistant Commissioner for Patents
BOX PATENT APPLICATION
Commissioner of Patents and Trademarks
Washington, D.C. 20231JC514 U.S. PTO
09/721881
11/27/00

Sir:

We are transmitting herewith the attached:

☒ **Patent Application Transmittal**☒ **Specification:****Total pages:** 26 (including claims and abstract): Spec. 20 sheets; Claims 5 sheets; Abstract - 1 sheet.☒ **Drawings:**

Total sheets: _____

☐ formal ☐ informal☒ **Combined Declaration and Power of Attorney:**

- ☐ newly executed
☐ copy from prior application
☐ Deletion of Inventor(s) - Signed statement attached deleting inventor(s) named in the prior application (37 CFR 1.63(d)(2) and 1.33(b))
☐ Incorporation by Reference - *The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied above is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.*

☒ **Accompanying application parts:**

- ☐ Notification of filing a
☐ Assignment of the Invention to Medtronic, Inc.
☐ Assignment cover sheet of prior application
☐ Information Disclosure Statement
☐ PTO Form 1449
☐ Copies of IDS citations
☐ Preliminary Amendment
☐ A copy of the Petition or Conditional Petition for Extension of Time in the prior application.
☒ Return Postcard

IF A CONTINUING APPLICATION:

- ☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP)
of prior application No. _____.
- ☐ Amend the specification by inserting before the first line the sentence: This application is a ☒ continuation
☐ division ☐ continuation in part of application number _____, filed _____.
- ☐ Cancel in this application original claims _____ of the prior application before calculating the filing fee.
(At least the original independent claim must be retained for filing purposes.)
- ☐ The prior application is assigned of record to Medtronic, Inc.
- ☐ The Power of Attorney in the prior application is to: Medtronic, Inc.

☐ This application claims the benefit of U.S. Provisional Application(s) Serial No.(s) _____, filed _____.

☒ Address all future correspondence to: Thomas F. Woods, Reg. No 36,726
Medtronic, Inc., MS 301
7000 Central Avenue NE
Minneapolis, Minnesota 55432
Telephone: (763)514-3652


FEE CALCULATION	No. of Claims Filed	Claims Included in Base Fee	No. of Extra Claims	Rate	Fee
Total Claims	21	20	= 1	x 18	\$ 18
Independent Claims	7	03	= 4	x 80	\$ 320
Multiple Dependent Claims				+ 260	
Basic Filing Fee					\$ 710
TOTAL					\$ 1048

☒ Charge Deposit Account No. 13-2546 the sum of **\$ 1048.00** (Filing Fee) for a total of **\$ 1048.00**

☒ The Commissioner is hereby authorized to charge any fees which may be required under 37 CFR 1.16 and 1.17, or credit any overpayment to Deposit Account No. 13-2546. A duplicate of this transmittal is enclosed.

Date

11-23-00


Thomas F. Woods, Reg. No. 36,726
MEDTRONIC, INC.
7000 Central Avenue N.E.
Minneapolis, Minnesota 55432
Telephone: (763) 514-3652
+31 43 356 6845

APPLICATION FOR UNITED STATES LETTERS PATENT

for

**STENTS AND METHODS FOR PREPARING STENTS FROM
WIRES HAVING HYDROGEL COATING LAYERS THEREON**

by

Michel Verhoeven

ATTORNEY OF RECORD:

Thomas F. Woods, Esq.
MEDTRONIC, INC.
7000 Central Avenue N.E.
Minneapolis, Minnesota 55432
Telephone: (612) 514-3652
Facsimile: (612) 514-3233

"Express Mail" Mailing Label Number _____

Date of Deposit _____

I hereby certify that this paper or fee is being deposited with the United States Postal Service
"Express Mail, Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above
and is addressed to Assistant Commissioner for Patents, Attn: **Box Patent Application**,
Washington, DC 20231.

Printed Name _____

Signature _____

5

10

15

25

35

examples of which may be found in the issued U.S. Patents listed in
Table 1 below.

Table 1: Prior Art Patents

	<u>Patent No.</u>	<u>Inventor(s)</u>	<u>Issue Date</u>
5	6,113,621	Wiktor	5 September 2000
	6,106,454	Berg et al.	22 August 2000
	6,100,474	McGregor et al.	8 August 2000
	6,077,413	Hafeli et al.	20 June 2000
10	5,980,551	Summers et al.	9 November 1999
	5,968,091	Pinchuk et al.	19 October 1999
	5,865,814	Tuch	2 February 1999
	5,843,158	Lenker et al.	1 December 1998
	5,837,313	Ding et al.	17 November 1998
15	5,837,008	Berg et al.	17 November 1998
	5,824,048	Tuch	20 October 1998
	5,776,184	Tuch	7 July 1998
	5,722,984	Fischell et al.	3 March 1998
	5,679,400	Tuch	21 October 1997
20	5,624,411	Tuch	29 April 1997
	5,607,463	Schwartz et al.	4 March 1997
	5,591,224	Schwartz et al.	7 January 1997
	5,554,181	Das	10 September 1996
	5,545,211	An et al.	13 August 1996
25	5,527,354	Fontaine et al.	18 June 1996
	5,525,356	Jevne et al.	11 June 1996
	5,464,650	Berg et al.	7 November 1995
	5,449,372	Schmaltz et al.	12 September 1995
	5,356,433	Rowland et al.	18 October 1994
30	5,336,518	Narayanan et al.	9 August 1994
	5,330,500	Song	19 July 1994
	5,163,958	Pinchuk	17 November 1992

5 All patents listed in Table 1 above are hereby incorporated by reference herein in their respective entireties. As those of ordinary skill in the art will appreciate readily upon reading the Summary of the Invention, Detailed Description of the Preferred Embodiments and Claims set forth below, many of the devices and methods disclosed in the patents of
10 Table 1 may be modified advantageously by using the teachings of the present invention.

SUMMARY OF THE INVENTION

20 The present invention has certain objects. That is, various
embodiments of the present invention provide solutions to one or more
problems existing in the prior art respecting radially expandable stents for
use in animals or humans. Those problems include inadequate
mechanical properties, lack of coating uniformity, surface roughness,
25 undesirable drug release properties, and inadequate biocompatibility.
Various embodiments of the present invention have the object of solving
at least one of the foregoing problems. While some radially expandable
stents were capable of solving at least some of the foregoing problems,
they were generally not employed because of their prohibitively high cost
30 or difficult manufacturing processes. It is therefore another object of the
present invention to provide an improved radially expandable stent that

may be manufactured and sold at low cost, yet still fulfill at least one of the foregoing objects.

In comparison to known radially expandable stents, various embodiments of the present invention may provide one or more of the following advantages. The present invention provides radially expandable stents with improved properties over stents known in the art. For example, stents of the present invention are preferably provided with a substantially uniform hydrogel coating layer thereon. Coating uniformity may be important in preventing complications such as clotting that occurs during use when uncoated wire surfaces of the stent are exposed to blood.

The present invention also provides advantageous methods for producing such stents. Methods of the present invention allow the wire to be coated by a continuous process. Such continuous coating processes may provide economic advantages as well as product quality improvements. For example, continuous coating methods of the present invention preferably provide substantially uniform coatings with low surface roughness. Low surface roughness may be desirable for handling and inserting the stent into the body, and may also contribute to the reduction of blood clotting that is observed when the surface of a stent is exposed to bodily fluids such as blood.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

As used herein, "substantially uniform coating" means that the wire surface is completely covered by the coating. Preferably the stent has a coating with a uniform dry thickness of at least about 0.1 micrometer and more preferably at least about 5 micrometers. Preferably the stent has a coating with a uniform dry thickness of at most about 25 micrometers and more preferably at most about 10 micrometers. Preferably the stent has a dry coating thickness with a relative standard deviation of no greater than about 10 percent.

As used herein, "surface roughness" refers to root mean square roughness (RMS or R_q).

As used herein, "low surface roughness" means that sharp edges are substantially absent when the surface is observed using light
5 microscopy at a 50 power magnification.

As used herein, "functional surface" means that the polymer used for the coating has at least the specified functional groups. The polymers can also include other functional groups. The polymers having such functional groups (amide groups, amine groups, etc.) are referred to
10 herein as "functionalized" polymers.

A "hydrogel" is a 3-dimensional network of cross-linked, hydrophilic macromolecules capable of being swelled and incorporating about 20 percent to about 95 percent water by weight. Hydrogels may include hydrophilic polymers that absorb water, thereby changing
15 mechanical properties. Examples of natural hydrogels include fibrin, collagen, elastin, and the like.

As used herein, "body lumen" means the inner open space or cavity of a tubular organ of the body, for example, a blood vessel or an intestine.

20 A "biocompatible" material is one that does not generally cause significant adverse reactions (e.g., toxic or antigenic responses) in the body, whether it degrades within the body, remains for extended periods of time, or is excreted whole. Ideally, a biocompatible material will not induce undesirable reactions in the body as a result of contact with bodily
25 fluids or tissue, such as tissue death, tumor formation, allergic reaction, foreign body reaction (rejection), inflammatory reaction, or blood clotting, for example.

As used herein, "biologically active agent" means a substance that has an effect on living tissue. Biologically active agents include, for
30 example, therapeutic agents, which are substances that tend to prevent and/or overcome disease and/or promote recovery. As such, biologically

active agents also include, for example, biologically active molecules (biomolecules) such as drugs.

As used herein, "modifying cellular response" means increasing, decreasing, causing, or eliminating a response by cells to a disease, an injury, or a foreign body.

In one aspect, the present invention provides a radially expandable stent that includes a wire having a hydrogel coating layer thereon. Preferably the coating layer is substantially uniform. More preferably the stent has a hydrogel coating layer with an average dry coating thickness (T) of about 0.1 micrometer to about 25 micrometers, a standard deviation (), and a relative standard deviation ($100 \times / T$) of no greater than about 10 percent. The hydrogel coating layer may optionally include a biologically active agent. The coating layer preferably provides a hydrophilic, biocompatible surface.

In another aspect, the present invention provides a method for preparing a radially expandable intravascular stent, and stents that are preparable and, preferably, prepared by such a method. The method includes providing a metal wire; applying to the wire a solution that includes a solvent and a water soluble polymer in the solvent; evaporating the solvent to provide a polymeric coating on the wire; crosslinking the polymeric coating to provide a hydrogel coating layer on the wire; and fabricating the coated wire into a cylindrical, radially expandable stent body. Preferably the solution is applied to the wire by a continuous coating method such as, for example, passing the wire through the solution at a substantially constant speed. The hydrogel coating layer may optionally be swollen with water prior to fabricating the coated wire into a stent.

In another aspect, the present invention provides a method for delivery of a biologically active agent to the interior of a body lumen. In one embodiment, the method includes providing a metal wire; applying to the wire a solution that includes a solvent, a water soluble polymer in the solvent, and a biologically active agent dispersed in the solvent;

09721331.12700

evaporating the solvent to provide a polymeric coating on the wire;
crosslinking the polymeric coating to provide a hydrogel coating layer on
the wire; fabricating the coated wire into a cylindrical, radially expandable
stent body; introducing the stent body transluminally into a selected
5 portion of the body lumen; and radially expanding the stent body into
contact with the body lumen. In another embodiment, the method
includes providing a metal wire; applying to the wire a solution that
includes a solvent and a water soluble polymer in the solvent;
evaporating the solvent to provide a polymeric coating on the wire;
10 crosslinking the polymeric coating to provide a hydrogel coating layer on
the wire; fabricating the coated wire into a cylindrical, radially expandable
stent body; applying a biologically active agent to the hydrogel coating
layer; introducing the stent body transluminally into a selected portion of
the body lumen; and radially expanding the stent body into contact with
15 the body lumen.

In another aspect, the present invention provides a method of
modifying cellular response in a body lumen to a disease, injury, or
foreign body. In one embodiment, the method includes providing a metal
wire; applying to the wire a solution that includes a solvent, a water
20 soluble polymer in the solvent, and a biologically active agent dispersed
in the solvent; evaporating the solvent to provide a polymeric coating on
the wire; crosslinking the polymeric coating to provide a hydrogel coating
layer on the wire; fabricating the coated wire into a cylindrical, radially
expandable stent body; introducing the stent body transluminally into a
25 selected portion of the body lumen; radially expanding the stent body into
contact with the body lumen; and controllably releasing the biologically
active agent into the body lumen. In another embodiment, the method
includes providing a metal wire; applying to the wire a solution that
includes a solvent and a water soluble polymer in the solvent;
30 evaporating the solvent to provide a polymeric coating on the wire;
crosslinking the polymeric coating to provide a hydrogel coating layer on
the wire; fabricating the coated wire into a cylindrical, radially expandable

5 the body lumen.

10

15

25

30

percent to about 95 percent water by weight. Hydrogel coating may be prepared by coating a solution of a water soluble polymer, and then crosslinking the polymeric coating. The crosslinking reaction may occur during a drying step or as a separate step.

5 Hydrogel coating solutions useful for articles and methods of the present invention include a water soluble polymer dissolved, dispersed, or suspended in a solvent to provide a coating solution. Optionally, the coating solution may contain other functional and/or non-functional additives including, but not limited to, initiators, crosslinking agents,
10 biologically active agents, and polymers with functional groups. Preferably the coating solution includes at least about 1 percent by weight polymer and more preferably at least about 10 percent by weight polymer. Preferably the coating solution includes at most about 90 percent by weight polymer and more preferably at most about 25 percent
15 by weight polymer.

 Hydrogel coatings useful for articles and methods of the present invention may be selected by using appropriate screening tests. Such exemplary tests include a coil test. In such a test, a coated wire is coiled around a stainless steel wire of 2 mm thickness that is being rotated at
20 100 revolutions per minute. The resulting coil of coated wire is then visually analyzed using light microscopy at a 50 power magnification. The coated wire may be tested as either in the dried state or in the swollen state that results from immersion in a fluid, preferably an aqueous fluid such as, for example, saline or water. Coatings tested in
25 the swollen state that show no visible cracks using this coiling method are considered mechanically stable and suitable as wire coatings for stents and methods of the present invention. Preferably the coatings show no visible cracks when tested in the dry state using this coiling method.

30 Polymers that may be used to prepare hydrogel coatings useful for articles and methods of the present invention preferably have substantial flexibility. Flexibility may arise from the use of a polymer with a low T_g , for

example, a polymer with a T_g of less than about 25°C. Alternatively, a polymer with a higher T_g may be swollen or plasticized to achieve adequate flexibility. In the case of hydrogels, the presence of water may lead to the desired flexibility.

- 5 Polymers that may be used to prepare solvent based coatings useful for articles and methods of the present invention preferably are not only flexible, but also have substantial toughness. Flexibility and toughness may arise, for example, from the use of polymers that contain both hard and soft segments, with the hard segments being, for example,
10 crystalline segments (e.g., having both amorphous and crystalline segments).

- Crosslinking the polymers during or after the coating process may also develop adequate toughness. Preferably the solvent coating solution includes low T_g (e.g., a T_g of less than about 25°C) crosslinkable
15 polymers (e.g., hydrogels). The level of crosslinking may be controlled to provide the desired physical properties (e.g., toughness, rate of drug release, etc.).

- Polymers useful in the present invention include polymers that are soluble, dispersable, or suspendable in the particular solvent being used.
20 Organic polymers having hydrocarbon backbones are preferred. Useful polymers include, but are not limited to, poly(hydroxyethyl methacrylate) (pHEMA), poly(vinylpyrrolidinone) (PVP), poly(acrylamide) (pAM), and poly(acrylic acid) (pAA). Preferably the polymer is chosen so as to adhere to the wire and to provide a hydrophilic surface after coating and
25 drying. More preferably the polymer provides a biocompatible surface or a functional surface that can be modified to provide a biocompatible surface.

- Solvents useful in coating solutions for articles and methods of the present invention include solvents that can be removed from the coated
30 wire at drying temperatures of about 50°C to about 200°C. Useful solvents generally have a boiling point of about 40°C to about 200°C. Solvents useful in coating solutions of the present invention include, for

example, tetrahydrofuran, acetone, ethanol, isopropanol, water,
methylene chloride, chloroform, hexane, heptane, xylenes, and toluene.

Crosslinking agents may optionally be added to the coating
solution to modify the physical and chemical properties of the dried
5 coating as desired. Suitable crosslinking agents include, but are not
limited to, functional, multifunctional, and polyfunctional materials,
including, for example, acrylate, acrylamide, or epoxide functionalities.
When crosslinking agents are used, they are typically added in about 0.1
percent by weight to about 50 percent by weight based on the weight of
10 the polymer.

When crosslinking agents are used in the solvent coating, initiators
may be added to facilitate crosslinking. For example, when polyacrylate
crosslinking agents are used, a free-radical generating initiator may be
included. Suitable free-radical generating initiators may be activated by
15 light or heat. Preferred initiators include, for example, ammonium
persulfate. When initiators are used, they are typically added in about
0.0001 percent by weight to about 0.01 percent by weight based on the
weight of the monomer.

Coating methods known in the art may be used to apply the
20 coating solution to the wire for articles and methods of the present
invention. Preferably the method is a continuous coating method. A
particularly useful method for applying coatings for articles and methods
of the present invention is to pass a wire at a substantially constant
speed through the coating solution. For example, the wire may be pulled
25 in a vertical direction from the solution to provide a substantially uniform
coating. Optionally, the wire may be passed through a die to remove
excess coating. When using continuous coating methods, useful coating
speeds will depend on factors such as the percent solids of the coating
solution, viscosity of the coating solution, and temperature of the coating
30 solution. Preferably the wire may be coated at about 1 lineal meters per
minute to about 100 lineal meters per minute. The temperature of the

coating solution may be maintained at any temperature desired, for example, at 25°C.

After the coating is applied, it may be dried by methods known in the art. Suitable drying methods include, but are not limited to,

- 5 conduction drying, convection drying, hot air impingement, steam treatment, infrared irradiation, ultraviolet irradiation, and microwave irradiation. Preferably the coating is dried by the application of heat. Preferably the coated wire is dried with air at a temperature of about 50°C to about 200°C for about 0.01 second to about 100 seconds.

- 10 Preferably the coating is applied so as to result in a dry coating thickness of at least about 0.1 micrometer and preferably at least about 5 micrometers. Preferably the coating is applied so as to result in a dry coating thickness of at most about 25 micrometers and more preferably at most about 10 micrometers.

- 15 Preferably the coating and drying methods are selected so as to provide a substantially uniform coating. Adequate uniformity may be determined by visually inspecting the coated wire to ensure that no uncoated wire is exposed. Alternatively, surface uniformity of the coating may be measured by field emission spectrometry (FEM), with a
20 substantially uniform coating showing complete coverage of the wire.

- Preferably the coating and drying methods are selected so as to provide a coating with a substantially uniform thickness as measured by the standard deviation (). Preferably for a coating of dry thickness T , the relative standard deviation ($100 \times \text{standard deviation} / T$) is no greater than about 10
25 percent.

- Preferably the coating and drying methods are selected so as to provide a coating with low surface roughness. Surface roughness may be measured using, for example, laser profilometry. Preferably the relative surface roughness ($100 \times R_q / T$) is at most about 25 percent and
30 more preferably at most about 10 percent. Alternatively, the surface roughness may be qualitatively evaluated by microscopic examination. Generally, the uncoated wire surface visually appears to have a rougher

5 polished in order to obtain stents with good surface roughness properties.

10 of the biologically active agents. The rate and degree of swelling may be
chosen to provide the desired release properties.

15 preparing the stent. Initially a wire is preformed by folding into a two-
dimensional zig-zag pattern, typically a sinusoidal pattern. A length of
the patterned wire under little or no tension is then wound around a
mandrel, and the mandrel removed to provide a radially expandable
stent. The fabrication may be carried out with dried or wet coatings. If
20 desired, the fabrication can be carried out by folding the wire while the
wire is immersed in a solution. For example, when using hydrogel
coatings, it is useful to fabricate the stent with the wire immersed in water
to maintain the hydrogel coating in the wet or swollen state. Alternatively,
the solvent coated wire may also be fabricated into stents using other
25 techniques known in the art.

30 applied to the coated hydrogel layer, the application may take place either before or after the coated wire has been fabricated into a stent as desired. The biologically active agent may be applied to the hydrogel

09731881 "112700

coating in either the dry or the wet state. Application of the biologically active agent to the hydrogel coating in the wet or swollen state is preferred for incorporating the biologically active agent more uniformly throughout the coating. Suitable application methods include, for example, dip coating. Biologically active agents may be added to stents to provide, for example, biocompatible surfaces. Useful biologically active agents include, but are not limited to, dipyridamole, heparin, anti-platelet drugs, anti-thrombogenic drugs, anti-proliferative drugs, and anti-mitotic drugs. When biologically active agents are used, they are typically added in about 0.1 percent by weight to about 25 percent by weight based on the weight of the polymer.

Coatings used in the stents and methods of the present invention may be selected and formulated to controllably release biologically active agents at the desired rate. The rate of release may depend on, for example, the amount and type of biologically active agent present in the coating and the temperature and conditions of the desired release. The rate of release may also depend on the properties of the selected polymer including, for example, solubility and polarity. Other factors may also effect the rate of release including, for example, crosslink density.

The surface coated radially expandable stents of the present invention may also be used for immobilizing biologically active agents. For example, when polyacrylamide is used as the wire coating, an amide-functional surface is obtained. The amide functional surface may be converted to an amine-functional surface by the Hoffman degradation process as described in copending U.S. Pat. Application Serial No. 09/245,834 filed 8 February 1999 entitled "METHOD FOR ATTACHMENT OF BIOMOLECULES TO SURFACES THROUGH AMINE-FUNCTIONAL GROUPS." Biologically active agents (e.g., periodate-activated heparin, collagen) may be readily coupled to the amine-functional surface. See, for example, U.S. Pat. Nos. 5,607,475 and 5,679,659.

Biologically active agents may be attached in an appropriate amount and orientation effective to provide, for example, an improved nonthrombogenic surface relative to the substrate without the biologically active agent. The present invention provides relatively high biologically active agent loading capacities (often as high as 50 micrograms of biologically active agents per square centimeter of modified surface) and bioactivities (often as high as 1.0 International Unit (IU) thrombin (IIa) deactivated per square centimeter of modified surface).

The present invention is illustrated by the following examples. It is to be understood that the particular examples, materials, amounts, and procedures are to be interpreted broadly in accordance with the scope and spirit of the invention as set forth herein.

EXAMPLES

Hydroxyethyl methacrylate (HEMA, 99.9 percent purity) was obtained from Kodak (Rochester, NY). Electrophoresis grade acrylamide (99.9 percent purity) was obtained from Aldrich Chemicals Inc. (Milwaukee, WI). Polyvinylpyrrolidone (povidone, PVP, Average M_w ca. 1,300,000 daltons) was obtained from Aldrich Chemicals Inc. (Milwaukee, WI). Ammonium persulfate was obtained from Aldrich Chemicals Inc. (Milwaukee, WI). Deionized water was used for all reactions.

Example 1

A solution of poly(hydroxyethyl methacrylate) is prepared by free radical polymerization of hydroxyethyl methacrylate (20 percent by weight) in water using ammonium persulfate initiator (up to 0.01 percent by weight) at 50°C. Prior to use as a coating solution, a bis-acrylate is added up to a concentration of about 0.01 percent by weight.

Example 2

A solution of polyacrylamide is prepared by free radical polymerization of acrylamide (20 percent by weight) in water using

5

A solution of poly(vinyl pyrrolidone) is prepared by dissolving PVP (20 percent by weight) in water. Prior to use as a coating solution, vinyl pyrrolidone is added up to a concentration of about 5 percent by weight and an initiator is added up to a concentration of about 0.01 percent by weight.

The solutions prepared in Examples 1-3 are used to coat stainless steel wire (125 micrometers thick, Fort Wayne, IN) and tantalum wire (125 micrometers thick, Fort Wayne, IN) in a continuous process. Each wire is pulled through a solution of the desired polymer at a rate of 1 to 2 meters/second into an infrared drying oven of approximately 1 meter in length at about 100°C. The wires are completely covered indicating the application of a substantially uniform coating.

20

30

16

weight, and an initiator was added up to a concentration of about 0.01 percent by weight. Unfractionated heparin (Diosynth, Oss, NL) was added to the solution at a concentration of up to 5 percent by weight. Stainless steel wires and tantalum wires were coated and dried as described in Example 4 to give a dry coating thickness of 5 micrometers.

Pieces of wire were incubated with a solution of phosphate buffered saline at 37°C. Samples were taken over time and assayed for heparin activity via determination of the rate of inactivation of a thrombin-antithrombin III mixture. It was concluded that approximately 15 percent of the heparin that was incorporated in the coating was released within 2 hours. Additional incubation of the coating resulted in a much slower release (10 percent in two days).

Example 6

A solution of poly(vinyl pyrrolidone) was prepared by dissolving PVP (20 percent by weight) in water. Prior to use as a coating solution, vinyl pyrrolidone was added up to a concentration of about 5 percent by weight, and an initiator was added up to a concentration of about 0.01 percent by weight. Dipyridamole (Merck, Darmstadt, GDR) was added to the solution at a concentration of up to 20 percent by weight. Stainless steel wires and tantalum wires were coated and dried as described in Example 4 to give a dry coating thickness of 5 micrometers.

Pieces of wire were incubated with phosphate buffered saline (pH=7.4) at 37°C. The solution was assayed periodically using ultraviolet-visible spectrometry. During the first 90 minutes approximately 20 percent of the drug was released. This burst was followed by release at a much slower rate. Additional incubation of the wire during a period of two days gave an additional release of 10 percent.

Example 7

Stainless steel wires and tantalum wires were coated with PVP and dried as described in Example 4 to give a dry coating thickness of

approximately 4 micrometers. Pieces of coated wire were incubated with
a Na_2CO_3 buffer (pH=10) at 60°C for one hour to induce hydrolysis of
some of the vinyl pyrrolidone rings. After thorough rinsing, the pieces
were soaked in a solution of 0.5 percent by weight poly(allylamine) ($M_w =$
5 1500, Aldrich), in a 0.25M 4-morpholineethanesulfonic acid solution
(pH=5.5) containing 0.05M 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride. The reaction was
allowed to proceed for one hour at room temperature after which the
samples were rinsed with deionized water.

10 A solution of unfractionated heparin (5 mg/ml) in 0.05M phosphate
buffer (pH=6.88) was prepared. NaIO_4 (0.065 mg/ml, Aldrich) was added
to the solution to induce periodate oxidation for introduction of aldehyde
groups into the heparin chains. The reaction was allowed to proceed for
3 hours at room temperature.

15 The resulting solution was diluted 1:5 by volume with 0.4M acetate
buffer (pH=4.66). NaBH_3CN (0.4 mg/ml, Aldrich) was added and the
aminated samples were incubated with the resulting periodate oxidized
heparin solution for 18 hours at room temperature. The samples were
then rinsed with deionized water, 1 M NaCl, and deionized water again.

20 Staining of the samples with Toluidine blue revealed an abundance of
immobilized heparin.

Incubation of the heparinized samples with a solution of
antithrombin III resulted in adsorbed activated antithrombin III that was
capable of deactivation of thrombin when contacted with a solution
25 containing the latter. This showed that the immobilized heparin was
bioactive.

The complete disclosure of all patents, patent applications, and
publications, and electronically available material cited herein are
30 incorporated by reference.

The preceding specific embodiments are illustrative of the practice
of the invention. It is to be understood, therefore, that other expedients

- known to those skilled in the art or disclosed herein, may be employed without departing from the invention or the scope of the appended claims. For example, the present invention is not limited to methacrylate, acrylamide, or poly(vinyl pyrrolidone) based hydrogel coated stents. The
- 5 present invention is also not limited to hydrogel coated stents *per se*, but may find further applications such as, for example, biocompatible medical devices. The present invention further includes within its scope methods of making and using the stents described hereinabove.

What is claimed is:

1. A radially expandable stent comprising a wire having a substantially uniform hydrogel coating layer thereon.
2. The stent of claim 1 wherein the layer has an average dry coating thickness of about 0.01 micrometer to about 25 micrometers.
3. The stent of claim 1 wherein the thickness of the coating has a relative standard deviation of no greater than about 10 percent.
4. The stent of claim 1 wherein the layer further comprises a biologically active agent.
5. The stent of claim 4 wherein the biologically active agent comprises a substance selected from the group consisting of dipyridamole, heparin, anti-platelet drugs, anti-thrombogenic drugs, anti-proliferative drugs, anti-mitotic drugs, and combinations thereof.
6. The stent of claim 1 wherein the layer provides a hydrophilic surface.
7. The stent of claim 1 wherein the layer provides a biocompatible surface.
8. A radially expandable stent comprising a wire having a hydrogel coating layer thereon, wherein the stent is preparable by a method comprising:
 - providing a metal wire;
 - applying to the wire a solution that includes a solvent and a water soluble polymer in the solvent;
 - evaporating the solvent to provide a polymeric coating on the wire;

crosslinking the polymeric coating to provide a hydrogel coating layer on the wire; and

fabricating the coated wire into a cylindrical, radially expandable stent body.

9. The stent of claim 8 wherein the solution is applied to the wire by a continuous coating method.

10. The stent of claim 9 wherein the continuous coating method comprises passing the wire through the solution at a substantially constant speed.

11. The stent of claim 8 wherein the hydrogel coating layer is swollen with an aqueous fluid prior to fabricating the coated wire into a stent.

12. A method for making a radially expandable intravascular stent comprising:

providing a metal wire;

applying to the wire a solution that includes a solvent and a water soluble polymer in the solvent;

evaporating the solvent to provide a polymeric coating on the wire;

crosslinking the polymeric coating to provide a hydrogel coating layer on the wire; and

fabricating the coated wire into a cylindrical, radially expandable stent body.

13. The method of claim 12 wherein the solution is applied to the wire by a continuous coating method.

14. The method of claim 13 wherein the continuous coating method comprises passing the wire through the solution at a substantially constant speed.
15. The method of claim 12 wherein the hydrogel coating layer is swollen with an aqueous fluid prior to fabricating the coated wire into a stent.
16. The method of claim 12 wherein the hydrogel coating layer has an average dry coating thickness of about 0.01 micrometer to about 25 micrometers.
17. The method of claim 12 wherein the thickness of the hydrogel coating layer has a relative standard deviation of no greater than about 10 percent.
18. A method for delivery of a biologically active agent to the interior of a body lumen comprising:
- providing a metal wire;
 - applying to the wire a solution that includes a solvent, a water soluble polymer in the solvent, and a biologically active agent dispersed in the solvent;
 - evaporating the solvent to provide a polymeric coating on the wire;
 - crosslinking the polymeric coating to provide a hydrogel coating layer on the wire;
 - fabricating the coated wire into a cylindrical, radially expandable stent body;
 - introducing the stent body transluminally into a selected portion of the body lumen; and
 - radially expanding the stent body into contact with the body lumen.

controllably releasing the biologically active agent into the body lumen.

21. A method of modifying cellular response in a body lumen to a disease, injury, or foreign body, comprising:
- providing a metal wire;
 - applying to the wire a solution that includes a solvent and a water soluble polymer in the solvent;
 - evaporating the solvent to provide a polymeric coating on the wire;
 - crosslinking the polymeric coating to provide a hydrogel coating layer on the wire;
 - fabricating the coated wire into a cylindrical, radially expandable stent body;
 - applying a biologically active agent to the hydrogel coating layer;
 - introducing the stent body transluminally into a selected portion of the body lumen;
 - radially expanding the stent body into contact with the body lumen;
 - and
 - controllably releasing the biologically active agent into the body lumen.

ABSTRACT

**STENTS AND METHODS FOR PREPARING STENTS FROM WIRES
HAVING HYDROGEL COATING LAYERS THEREON**

Radially expandable stents having hydrogel coating layers thereon, and methods of preparing such stents are disclosed. The methods include coating a wire with a solution that includes a solvent and a water soluble polymer in the solvent, evaporating the solvent to provide a polymeric coating on the wire, and crosslinking the polymeric coating to provide a hydrogel coating layer on the wire. The coated wire can be fabricated into stents, which preferably have substantially uniform coatings with low surface roughness. Preferably the coatings have hydrophilic properties and provide a biocompatible surface. The coatings may also provide for the delivery of biologically active agents into the body.